Estrategia en EPOC del Sistema Nacional de Salud

19
Soler-Cataluña JJ, Martínez-García MA, Sánchez L, Perpiña T, Román S. Severe
exacerbations and BODE index: two independent risk factors for death in COPD patients.
Respir Med. 2009 May; 103(5): 692-9. Epub 2009 Jan 7
20 Filkenstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to
emphysema in smokers. Am J Respir Crit Care Med. 1995; 152: 1666-1672.
21 O’Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of
subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J
Respir Crit Care Med. 1997; 155: 852-857.
22 Saetta M, Di-Stefano A, Turato G, Facchini FM, Corbino L, Mapp CE et al. CD8+ T­
lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med. 1998; 157: 822-826.
23 Dharmage SC, Erbas B, Jarvis D, et al. Do childhood respiratory infections continue to
influence adult respiratory morbidity. Eur Respir J. 2009; 33: 237-244
24 Molfino NA. Genetics of COPD. Chest. 2004; 125: 1929-1940
25 Birring SS, Brightling CE, Bradding P, Entwisle JJ, Vara DD, Grigg J et al. Clinical, radiologic,
and induced sputum features of chronic obstructive pulmonary disease in non-smokers: a
descriptive study. Am J Respir Crit Care Med. 2002; 166(8):1078-83.
26 Tonnesen P, Carrozzi L, Fagerström KO, Gratziou C, Jimenez-Ruiz C, Nardini S et al.
Smoking cessation in patients with respiratory diseases: a high priority, integral component of
therapy. Eur Resp J. 2007; 29: 390-417.
27 Jiménez Ruiz CA, Sobradillo Peña V, Miravitlles M y cols. Análisis de tabaquismo en España
a la luz de los resultados del estudio IBERPOC. Prev Tab. 2000; 2: 189-193.
28 Wagena EJ, Zeegers MPA, Van Schayck CP, Wouters EFM. Benefits and risks of
pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug
Saf. 2003; 26: 381-403.
29 Jiménez Ruiz CA, Barrueco Ferrero M, Solano Reina S, Torrecilla Garcia M, Domínguez
Grandal F, Diaz-Maroto Muñoz JL et al. Recomendaciones en el abordaje diagnóstico y
terapéutico del tabaquismo. Documento de consenso. Arch Bronconeumol. 2003; 39: 35-41
30 Jiménez CA, Masa F, Miravitlles M, Gabriel R, Viejo JL, Villasante C et al. Smoking
characteristics: attitudes and dependence. Differences between healthy smokers and smokers
with COPD. Chest 2001; 119: 1365-1370.
31 Rodriguez E, Ferrer J, Martí S, et al. Impact of occupational exposure on severity of COPD.
Chest. 2008; 134: 1237-1243.
32 Soriano JB, Miravitlles M. Datos epidemiológicos de EPOC en España. Arch Bronconeumol.
2007; 43: Supl 1:2-9.
33 Instituto Nacional de Estadística. INE. Notas de Prensa. Defunciones según la causa de
muerte en el año 2001. Disponible en URL: http://www.ine.es/prensa/np313.pdf. Ultimo acceso:
Abril 2008.
34
Instituto Nacional de Estadística. INE. Diario de Salud 2003-2004. Disponible en
www.ine.es/prodyser/pubweb/espcif/salu0304.pdf. Ultimo acceso: Abril 2008.
35 Encuesta Nacional de Salud 2006 Disponible en:
www.msc.es/estadEstudios/estadisticas/encuestaNacional/home.htm. Ultimo acceso: Abril 2008
36 Centro Nacional de Epidemiología. Instituto de Salud Carlos III, Ministerio de Ciencia e
Innovación [Internet]. Disponible en:
www.isciii.es/htdocs/centros/epidemiologia/epidemiologia_presentacion.jsp. Ultimo Acceso:
Abril 2008
37 Miravitlles M, Ferrer M, Pont A, Viejo JL, Masa JF, Gabriel R, et al. Characteristics of a
population of COPD patients identified from a population-based study. Focus on previous
diagnosis and never smokers. Respir Med. 2005; 99: 985-995.
38 Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of
COPD: systematic review and meta-analysis. Eur Respir J. 2006; 28: 523-532.
192